文献速递肾癌与肾肿瘤

经皮消融治疗与肾部分切除术治疗cT1a肾癌的比较:来自加拿大肾癌信息系统(CKCIS)的结果

A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System.
PubMed 文献 · J Urol · 2022-06-10

基于加拿大肾癌信息系统2011至2021年数据,275例接受经皮消融治疗(AT)、2001例接受肾部分切除术(PN)的cT1aN0M0肾癌患者纳入分析。经逆概率治疗加权(IPTW)倾向评分调整后,AT组2年无复发生存(RFS)为88.1%,低于PN组的97.4%(p<0.0001);5年RFS为86.0%对95.1%(p=0.003);总生存(OS)两组无显著差异。PN是疾病复发的预测因素(HR 0.36,p=0.003),但对OS无预测作用(HR 0.96,p=0.9)。结论认为随访时间短,PN提供更好的RFS,但OS无显著差异,两种方式均可用于合适选择的患者,尚待前瞻性随机数据。

要点

  • 经IPTW倾向评分调整后,AT组2年RFS为88.1%,PN组为97.4%(p<0.0001)。
  • 5年RFS在AT组为86.0%,PN组为95.1%(p=0.003);OS两组无显著差异。
  • PN是疾病复发的预测因素(HR 0.36,p=0.003),但对OS无预测作用(HR 0.96,p=0.9)。

核心结论

  • 在短期随访中,PN较AT提供更好的RFS,但经PS调整后OS无显著差异。
  • 两种方式均可提供给经过适当选择的患者,同时等待前瞻性随机数据。

研究设计与样本

  • 基于加拿大肾癌信息系统(CKCIS)的全国性数据,纳入2011至2021年接受PN或AT的cT1aN0M0肾癌患者。
  • 共纳入275例接受AT和2001例接受PN的患者,中位随访2.0年(IQR 0.6-4.1)。
  • 采用倾向评分(PS)的逆概率治疗加权(IPTW)进行分析,用Kaplan-Meier log-rank检验和Cox比例风险回归模型比较RFS和OS。

主要发现

  • IPTW PS分析后,AT组和PN组的2年RFS分别为88.1%和97.4%(p<0.0001)。
  • IPTW PS分析后,AT组和PN组的5年RFS分别为86.0%和95.1%(p=0.003)。
  • IPTW PS分析后,AT组和PN组的2年OS分别为97.4%和99.0%(p=0.7);5年OS分别为94.2%和95.1%(p=0.9)。
  • IPTW PS分析后,治疗方式(PN vs AT)是疾病复发的预测因素(HR 0.36,p=0.003),但对OS无预测作用(HR 0.96,p=0.9)。

临床怎么用

  • 作者认为,PN和AT均可提供给经过适当选择的患者,同时等待前瞻性随机数据。

局限性

  • 原文报告随访时间短。
  • 原文结论指出需等待前瞻性随机数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Percutaneous ablation therapy (AT) and partial nephrectomy (PN) are successful management strategies for T1a renal cancer. Our objective was to compare AT to PN with respect to recurrence-free survival (RFS) and overall survival (OS). MATERIALS AND METHODS: Patients post-PN or -AT for cT1aN0M0 renal cancer from 2011 to 2021 were identified from the national Canadian Kidney Cancer information system. Inverse probability of treatment weighting (IPTW) using propensity score (PS) was used. The primary outcomes, RFS and OS, were compared using Kaplan-Meier log-rank test analyses and Cox proportional hazard regression models. RESULTS: A total of 275 patients underwent AT and 2,001 underwent PN, with a median followup of 2.0 years (IQR 0.6-4.1). Covariates were well balanced between the AT and PN cohorts following PS matching. Two-year RFS following IPTW PS analysis for patients undergoing AT and PN was 88.1% and 97.4% (p <0.0001), respectively, while 2-year OS was 97.4% and 99.0% (p=0.7), respectively. Five-year RFS following IPTW PS analysis for patients undergoing AT and PN was 86.0% and 95.1%, respectively (p=0.003), while 5-year OS was 94.2% and 95.1%, respectively (p=0.9). Following IPTW PS analysis, treatment modality (PN vs AT) was a predictor of disease recurrence (HR 0.36, p=0.003) but not for OS (HR 0.96, p=0.9). CONCLUSIONS: With short followup, PN offers better RFS than AT, although no significant difference in OS was detected following PS adjustments. Both modalities can be offered to appropriately selected patients while we await prospective randomized data.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Millan B, Breau RH, Bhindi B, et al. A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System. J Urol. 2022. PMID: 35686812. doi:10.1097/JU.0000000000002798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。